Vesugen

What Is Vesugen?

Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (KED), one of the short peptide bioregulators developed and studied mainly by Russian gerontology researchers. In the literature it appears both as vesugen and as KED or Lys-Glu-Asp.^[1][2]

Published work frames vesugen as a vascular-oriented peptide: one paper describes a vasoprotective effect of vesugen reported earlier in older people and investigates it in vascular endothelial cell cultures.^[2] More recent reviews from the same research program discuss KED as a neuroprotective candidate in Alzheimer’s disease research.^[1][3]

Most of the evidence comes from cell and tissue culture experiments, reviews and computational docking. Two small human studies have also been published in a Russian gerontology journal, but neither is a randomized controlled trial.

Chemical Structure and Molecular Identity

Vesugen is L-lysyl-L-glutamyl-L-aspartic acid, a linear tripeptide with a free amino terminus and a free carboxylic acid terminus. PubChem lists it under CID 87571363 with the molecular formula C15H26N4O8, a molecular weight of 390.39 g/mol and CAS number 204271-66-9.

The molecule combines one basic residue, lysine, with two acidic residues, glutamic acid and aspartic acid, giving it several ionizable groups and high polarity; PubChem reports a computed XLogP of -7.4. All three residues have the natural L (S) configuration, and the InChIKey is LLSUNJYOSCOOEB-GUBZILKMSA-N.

Related sequences

The Lys-Glu-Asp motif forms the core of several other bioregulator peptides:

• Vilon (Lys-Glu) is the first two residues of vesugen.
• Testagen (Lys-Glu-Asp-Gly), livagen (Lys-Glu-Asp-Ala), prostamax (Lys-Glu-Asp-Pro) and pancragen (Lys-Glu-Asp-Trp) extend vesugen by one residue.
• Vesilut (Glu-Asp) is vesugen without its N-terminal lysine.

Research History and Development

In the PubMed record reviewed, research on vesugen dates from 2011, when it began appearing in organotypic tissue culture studies of aging cells. Early papers tested it alongside other short peptides such as vilon, epithalon, pancragen and bronchogen in pineal, pancreatic, bronchial and prostatic cell cultures.^[4][5]

From 2014 onward the work shifted toward proposed gene-level mechanisms. Researchers used molecular docking to model vesugen binding to gene promoter regions and published reviews suggesting that KED, vilon and epithalon could influence genes linked to aging and vascular disease.^[2][6][7]

Two clinical reports, published in 2015 and 2016, assessed vesugen together with pinealon in middle-aged and older adults using biological age indicators.^[8][9] Since 2021, reviews have focused on KED in the context of Alzheimer’s disease and neurogenesis.^[1][3] A 2024 review grouped Lys-Glu-Asp with other short peptides, including Lys-Glu, Glu-Trp and Glu-Asp-Arg, as multitarget agents with a wide range of activity and argued for a comprehensive approach to Alzheimer’s therapy over the classical one.^[3]

Mechanisms Studied in Research

The proposed mechanism for vesugen is epigenetic: the tripeptide is suggested to bind specific DNA sequences in gene promoters and change gene expression. This idea rests mainly on computational docking and expression studies in cultured cells, not on direct experimental proof in living organisms.

In vascular endothelial cell cultures from young and old animals, vesugen and a second peptide, D-7, raised expression of the proliferation protein Ki-67, which declines with age. Docking models placed both peptides on the core promoter of the MKI67 gene, which encodes Ki-67, through a CATC sequence near the transcription start site.^[2]

Reviews from the same research program report binding sites for Lys-Glu-Asp in the promoter of the gene for the cytokine MIC-1/GDF15 and propose that KED could influence F11R gene expression and synthesis of the adhesion molecule JAM-A.^[6][7] Both proposals are presented as possibilities rather than demonstrated effects.

A 2021 review summarizing published and unpublished findings concluded that KED regulates genes tied to cell aging and apoptosis (p16, p21), neuronal differentiation (NES, GAP43 and their proteins nestin and GAP43) and Alzheimer’s disease pathogenesis (SUMO, APOE, IGF1). It also states that KED restored synaptic plasticity in an in vitro Alzheimer’s model and calls for testing in animal models.^[1]

Key Findings From Published Studies

Published findings on vesugen are mostly cell culture results on proliferation and aging markers, plus two small uncontrolled human studies of biological age. Findings are grouped below by type of evidence.

Cell and tissue culture studies

• Neuroimmunoendocrine cultures: Lys-Glu-Asp stimulated proliferation and inhibited apoptosis in organotypic cultures, raising Ki-67 and lowering p53 in pineal tissue, with a stronger effect in cultures from old animals. The same report describes modulation of associative learning in honey bees in short- and long-term memory models.^[10]
• Pineal immune cells: vesugen did not change the differentiation of pineal lymphoid cells but enhanced their proliferation potential, unlike vilon and epithalon, which shifted differentiation.^[4]
• Prostatic fibroblasts: vesugen stimulated expression of differentiation factors in human prostatic fibroblast cultures, with a stronger effect in late-passage (aged) cultures.^[5]
• Skin fibroblasts: KED inhibited MMP-9 synthesis and increased Ki-67 and CD98hc in aging fibroblast cultures, but unlike AED and AEDG it was not reported to suppress caspase-dependent apoptosis.^[11]

Human studies

In a study of 32 adults aged 41 to 83 with chronic polymorbidity and organic brain syndrome in remission, the authors reported an anabolic effect and improved biological age indicators with both vesugen and pinealon, with a more visible effect for vesugen. They also observed prooxidant activity and a decrease in CD34+ hematopoietic cells, which they interpreted as inhibition of hemopoiesis. The abstract does not describe a placebo group or randomization.^[8]

A comparative monitoring study of 110 people found the largest effect on biological age indicators when vesugen and pinealon were used together, compared with dry carbon dioxide baths, hyperbaric oxygen and therapeutic massage. Massage and the peptide preparations were rated the safest on biochemical, immunological and clinical parameters.^[9] A 2021 review also states that KED improved memory and attention in elderly individuals with functional central nervous system disorders.^[1]

Evidence at a glance

Because several related peptides share the Lys-Glu-Asp motif, researchers typically confirm vesugen identity and purity with HPLC and mass spectrometry certificates of analysis.

Regulatory and Research Status

Vesugen is not an FDA-approved drug and has no approved medical use in the United States. It is a research compound in the US context.

The human data consist of small studies without a described control group, and the mechanistic work relies heavily on docking models and culture experiments from one research network. Independent replication, pharmacokinetic data and controlled clinical trials are not present in the PubMed record reviewed for this page.

Biological age, the main outcome in the human reports, is a composite of physiological and biochemical indicators rather than a clinical endpoint such as disease incidence or survival. Results on that measure are therefore hard to compare with conventional trial outcomes.

Findings such as changes in biological age indicators or memory measures are reported here as the authors’ results and should not be read as established effects of the peptide in humans.